SBP have just announced the appointment of Professor John Papadimitriou as a director . This has to be seen as step in the right direction for the proper management of what is a company with a huge potential in the bio tech field . Despite recent good annnouncements regarding trial work the share price is well below its potential. Especially SBPOA which offers great leverage.